← Back to Search

Cardiac Myosin Inhibitor

Mavacamten Dose 1 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to day 80

Awards & highlights

Study Summary

This trial will compare the effects of two different doses of a drug on healthy people. #medtrial

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to day 80

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to day 80

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 80 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC [INF])

Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])

Maximum observed plasma concentration (Cmax)

Secondary outcome measures

Number of Participants with Adverse Events (AEs)

Number of Participants with Clinical Laboratory Abnormalities

Number of Participants with Electrocardiogram (ECG) Abnormalities

+5 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Mavacamten Dose 2Experimental Treatment1 Intervention

Group II: Mavacamten Dose 1Experimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Mavacamten

2022

Completed Phase 1

~340

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,430 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings available for enrollees in this research trial?

"Affirmative. Clinicaltrials.gov has verified that the trial, which was first uploaded on February 20th 2023, is presently searching for participants. 84 patients need to be enrolled from 2 distinct medical facilities."

Answered by AI

Has the Federal Drug Administration given its endorsement to Mavacamten Dose 1?

"Our Power team assigned Mavacamten Dose 1 a score of one, due to the limited safety and efficacy data available from its Phase 1 trial."

Answered by AI

Are individuals aged 70+ being considered for recruitment into this clinical trial?

"This study is open to participants aged 18 or older, with an upper age limit of 60."

Answered by AI

What is the current participant count for this experiment?

"Correct. Records hosted on clinicaltrials.gov affirm that this scientific experiment, which was first posted on February 20th 2023, is currently recruiting. A total of 84 participants must be enlisted from 2 different medical centres."

Answered by AI

Do I meet the criteria to participate in this research initiative?

"This clinical trial is accepting 84 participants of ages between 18 and 60 who meet the criteria for good health. In particular, they must have a BMI ranging from 18 to 32 kg/m^2; display normal results on physical examination, vital signs, 12-lead ECGs and laboratory tests (hematology, chemistry and urinalysis); possess CYP2C19 genotypes either *1/*1 or *17/*17."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

2023. "A Study to Evaluate the Effects of Mavacamten in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05719805.